IiSGM

L1: Value of liquid biopsy as a predictor of response in cancer patients.

Axis 2: International relations, alliances and visibility.

L1: Search for predictors of response to neoadjuvant chemotherapy with docetaxel carboplatin in patients with triple negative breast cancer.

L2: Development of preclinical PDXs models.

L3: Development of Organoids.

L4: Development of new technologies with impact on the oncology patient (FAITH).

Axis 3: Consolidation of innovation.

L1: Oncological Genetic Counselling.

Axis 4: Competitiveness (sustainability) and resources available for research.

L1: Development of murine breast cancer Tumorgrafts.

L2: Search for genomic profiles as predictors of response in oncology patient.

Axis 5: Quality and management of research and innovation.

L1: Immunotherapy for cancer disease

L2: Innovation in treatment of colorectal cancer.

L3: Innovation in treatment of gastric cancer.

L4: Innovation in treatment of lung cancer.

L5: Innovation in treatment of genitourinary tumours.

L6: Innovation in systemic treatment of brain tumours.

L7: Innovation in systemic treatment of melanoma.

L8: Innovation in the diagnosis of patients with stage I-III breast cancer.

L9: (Neo) adjuvant breast cancer chemotherapy